The healthcare industry presents a wealth of opportunities for investors to generate notable portfolio returns over decades.

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an ...

Dexcom announced the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes will ...

The global Blood Glucose Monitoring System Market, valued at US$15.16 billion in 2024, stood at US$16.46 billion in 2025 and ...

These healthcare stocks have long-term and profitable growth runways.

The DJS Law Group  reminds investors of a class action lawsuit against  DexCom, Inc. ("DexCom " or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule ...

DexCom (DXCM) just received FDA clearance for Smart Basal, a new device designed to help adults with Type 2 diabetes optimize their insulin dosing using personalized, real-time sensor data. This ...

Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next ...

DexCom receives FDA clearance for DexCom Smart Basal titration software module, which optimizes basal insulin dose in type 2 ...

Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plai ...

Levi & Korsinsky, LLP notifies investors in DexCom, Inc. (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DexCom investors who ...

CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered DexCom losses, you mayCLICK HERE or copy and paste the following link into your browser: ...